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THE DICTIONARY DEFINES PROGRESS AS “MOVEMENT TOWARD A GOAL.”
In the following iFORUM editorials, we have thoughtful arguments favoring and opposed to a more
detailed evaluation of patients with ST-segment elevation myocardial infarction (STEMI) before angio-
plasty and stent placement. Holmes and Lerman (See, Think, Act) argue that distinguishing between
plaque rupture and plaque erosion as the cause of STEMImight be helpful to personalize therapy, with the
goal of improving care and long-term outcome. By contrast, Moreno, King, and Sharma (Just Act) argue
thatmajor advances in the care of patientswith STEMI have beenmade over the last 3 decades supporting
the value of rapid restoration of flow and acute angioplasty/stent to treat residual stenosis in these
patients. This rapid definitive therapy has produced demonstrable improvement in patient outcome.
Moreno et al. argue that the incidence of plaque erosion as a cause of STEMI is likely to be low; additional
evaluation of patients before stent and angioplasty is unlikely to improve outcome.
Given our current state of understanding, it is apparent that much more data are necessary before
linical guidance is available about the role of optical coherence tomography (OCT) in the selection of
herapy in patients with STEMI. However, it is also clear that applying high-resolution intravascular imag-
ng with OCT will allow us to advance our understanding of the etiology of STEMI. That informationhould lead to progress.See, Think, Act
David R. Holmes JR, MD
mir Lerman, MD
“The feasibility of an operation is not the best
indication for its performance”
—Henry Lord Cohen of Birkenhead (1)
Patient care is always based on an anecdote—
the specific patient at hand. That anecdote
has personalized specific features, expecta-
tions, and concerns, each of which is indeedunique. To generalize care for subsequent pa-
tients on the basis of such an anecdotal case
(or, in this case, 2 cases) is fraught with diffi-
culty. However, to not think about the issues
identified or raised with such a case or even 2
cases is fraught with at least as much diffi-
culty and danger, the latter stemming from
failure to recognize new avenues of consider-
ation in terms of pathophysiology and treat-
ment strategies.
The current report describes a cohort of
patients presenting with STEMI without sig-
nificant severe coronary artery disease. Forty
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291percent of patients did not undergo
percutaneous coronary intervention
(PCI) and were only treated with dual
antiplatelet therapy, whereas 60% un-
derwent PCI and stenting. These
cases, although they might not neces-
sarily represent more typical patients
presenting with STEMI, raise the po-
tential role of endothelial cell activa-
tion, dysfunction, and inflammation
in acute coronary syndromes (ACS).
ACS, both STEMI and non-
STEMI, include a wide variety of path-
ological substrates, as have been docu-
mented by multiple autopsy series.
They also include a wide variety of clin-
ical settings about which we continue to
learn. As part of this process, therapeu-
tic strategies have continued to evolve,
and the field specifically of STEMI
treatment has continued to change in-
crementally from early reliance on lytic
therapy, next to conventional percutane-
ous transluminal coronary angioplasty,
then to bare-metal stents, and now to
drug-eluting stents “served with or
without thrombectomy.” These strate-
gies are aimed at mechanically treating
significant stenoses and not at passivat-
ing local arterial abnormalities/pathol-
ogy. As such, although effective in
TEMI patients, these therapeutic
trategies are typically deployed rather
ndiscriminately. A question to be ad-
ressed relates to how often there is a
evere stenosis when the inciting
hrombus has been removed. Old in-
ormation from the thrombolytic era
ight be relevant in this regard. In
lder studies of patients treated with
hrombolysis, approximately 10% to
0% of the infarct-related arteries af-
er successful thrombolysis have a re-
idual stenosis 50% to 60% (2–5).
ypically, these older studies did not
erform quantitative coronary angiog-
aphy, instead relying on visual assess-
ent, which typically over-calls theeverity of lesions. Accordingly, thelesion severity might have even been
less. Whether these patients had plaque
erosion as the putative pathophysiologi-
cal event, as suggested by these 2 cur-
rent cases, is impossible to determine.
In contrast to these evolving thera-
peutic strategies during STEMI, diag-
nostic strategies have not evolved to
as great a degree. Clinicians still rely
on the gold standard of ST-segment
elevation, which then drives the train
of reperfusion, where currently it al-
most seems as if STEMI equals stent.
The current study also raises the
role of intravascular imaging in the
setting of ACS. Imaging techniques
such as intravascular ultrasound and
OCT are not routinely performed in
the setting of STEMI. Thus, the true
incidence of these cases is not known
and might be underestimated. It is
Figure 1. Coronary Endothelial Dysfunction, Act
Formation Without Underlying Signiﬁcant Ather
Progression of the thrombus might result in an occ
coronary syndrome. The use of intracoronary imagi
anism and help with the clinical decision-making. R
lead to the progression of healed thrombus and oc
coronary syndrome but might present later as angforeseeable that many events mightbe clinically silent and contribute to
plaque progression and not to STEMI,
similarly to the natural history of plaque
rupture (Fig. 1). Thus, the application
of novel imaging strategies during the
course of ACS might modify our ap-
proach.
New diagnostic strategies are needed
so that physicians can base treatment
on the mechanisms of the specific clini-
cal scenario. Such new diagnostic strat-
egies might be expeditious as well as
safe and able to distinguish different
pathophysiological substrates. Intra-
coronary assessment seems to have
the best possibility in this regard. The
patient is already in the catheteriza-
tion laboratory, and the infarct-related
artery and culprit lesion have been iden-
tified. OCT, with its much greater
resolution as documented in this re-
ion, and Erosion Might Lead to Thrombus
erotic Plaque
ve thrombus and clinical presentation of acute
odalities can help identify this underlying mech-
ated episodes of nonocclusive thrombus might
ive disease without clinical manifestation of acuteivat
oscl
lusi
ng m
epe
clusport, is a very suitable modality. It has
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292the substantial theoretical and practi-
cal advantage over intravascular imag-
ing in terms of this improved resolu-
tion. It can be performed quickly.
However, it does require instrumenta-
tion with a guidewire, which although
very safe has occasional complica-
tions—although most of these relate to
the placement of guidewires, which
would be used anyway if PCI is per-
formed. Moreover, the extent to which
OCT is available in most catheteriza-
tion laboratories treating patients 24/7
for STEMI is unclear.
In the current report OCT was
used to rule out the presence of sig-
nificant atherosclerotic disease and
plaque rupture. Future development
of the technology might allow more
accurate imaging of specific inflam-
mation and plaque erosion.
This current editorial makes obser-
vations about intriguing unique cases
and should cause us to think, because
it might answer some of the issues of
modern-day acute care—in this partic-
ular case, the issue of plaque erosion
versus ruptured plaques. Do these cases
set the stage for a revolution in care—
perhaps analogous to fractional flow re-
serve, which has resulted in a change
from the concept of “see a lesion, treat
a lesion” to “see a lesion, make an as-
sessment (measurement) of what is
there (fractional flow reserve), then treat
what is there with the best therapy for
the specific patient”—for example, in
this case medical therapy versus PCI?
Certainly not, or at least not yet, how-
ever. We do not know what a subse-
quent series of cases like this would
esult in—whether that would be re-
urrent occlusion, recurrent infarction,
r continued stabilization as docu-
ented by the authors. Certainly re-
urrent occlusion, either silent or as-
ociated with recurrent infarction, has
een well-documented with all reper-
usion strategies for patients with pSTEMI. We do not know whether
such an event would have been very
frequent in subsequent patients, de-
spite our concentration on optimal
antiplatelet or antithrombotic therapy.
Perhaps in the future we will have
specific therapies for prevention of
endothelial cell activation or inflam-
mation, but that remains to be seen.
What then have we learned from
these cases?
1. There is still information to be
gained from careful assessment of
specific features in any patient pre-
senting with STEMI.
2. There is room for continued cre-
ative approaches to imaging as well
as treatment in these patients.
3. Constraining ourselves to just be
doers, however expert, robs us and
our patients of the potential for
creative thinking, problem solving,
and matching personalized treat-
ment strategies to the people we are
treating.
4. They raise the concept of personal-
ized treatment of ACS on the basis
of novel intravascular imaging.
Just Act
Pedro R. Moreno, MD
Spencer B. King III, MD
Samin K. Sharma, MD
W I T H I N T H E LAST 3 DECADES, IN-
HOSPITAL MORTALITY OF STEMI HAS DE-
CREASED FROM 15% TO 3% (6,7). This
mazing progress was possible because
f a consistent, sequential, and suc-
essful approach to restore coronary
ow during the first hours of the
vent. Starting with beta-blockers,
hrombolysis, and PCI, randomized
rials showed superiority for therapies
imed to achieve fast and effective
estoration of epicardial and microvas-
ular flow. Multiple randomized tri-
ls demonstrated PCI to be far su-
erior to thrombolytic therapy (8). uhe cardiovascular community rap-
dly embraced PCI for STEMI, with
ncredible improvements in early in-
ervention. Door-to-balloon time de-
lined from a median of 96 min in
005 to a median of 64 min in 2010.
he percentage of patients who had
imes 90 min increased from 44.2%
o 91.4% (9).
Recent randomized trials also sup-
orted thrombectomy as an adjunctive
herapy in the percutaneous treatment
f STEMI (10,11). As such, manual
hrombectomy followed by endurable
caffolding devices such as bare-metal
r drug-eluting stents is considered
he preferred therapy for STEMI to-
ay (12).
Occasionally, after successful me-
hanical thrombectomy, the interven-
ionalist might encounter an interest-
ng and controversial clinical situation:
he angiogram shows very little or
o residual stenosis. Plaque erosion
omes immediately as a possible sce-
ario. OCT can immediately confirm
he diagnosis (13). In these selected
ases, proceeding with stenting might
ot be absolutely critical for the im-
ediate treatment of the STEMI.
evertheless, there are no random-
zed, prospective data supporting
hrombectomy alone as the solo ther-
py for STEMI, independent of the
esidual stenosis. As such, avoiding
oronary stenting after thrombectomy
ight be considered non–evidence-
ased medicine.
Several aspects must be carefully
onsidered, to discuss thrombectomy
lone as a potential solo therapy for
atients with STEMI and no residual
tenosis. The interventionalist must
ave a comprehensive knowledge of
oronary thrombosis in STEMI, the
ncidence of plaque erosion in clinical
ractice, the risk of re-occlusion with
hrombectomy alone, and the routine
se of intracoronary imaging in
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293STEMI PCI. Finally, we should ad-
dress whether this is the right time
to change clinical practice.
Coronary thrombosis in STEMI. Three
ajor vascular events are responsible
or coronary thrombosis leading to
TEMI: plaque rupture, plaque ero-
ion, and calcific nodules. Plaque rup-
ure is by far the most common cause,
esponsible for 76% of STEMI (14).
he plaque underneath is a positively
emodeled, thin-cap fibroatheroma,
ith increased inflammation and neovas-
ularization. Macrophage-dependent
atrix metalloproteinases contribute to
he rupture of the fibrous cap (15). The
ighly thrombogenic necrotic core is
ow in direct contact with the lumen.
acrophage-expressed tissue factor in
he core leads to thrombin generation
nd platelet activation, ultimately re-
ponsible for occlusive atherothrombo-
is (16). In clinical practice, plaque
upture can be documented by OCT, as
hown in Figure 2. However, the great
ajority of patients are successfully
reated with thrombectomy followed by
oronary stenting.
The second most common cause of
oronary thrombosis in STEMI is
laque erosion. Classified by the late
ichael Davies as “other causes of
oronary thrombosis,” plaque erosion is
n evolving concept relevant in a
maller group of patients. The inci-
ence of plaque erosion in clinical prac-
ice is unknown. Autopsy studies sug-
est that it might be present in 15% to
0% of STEMI cases. However, path-
logical series in younger populations
uggest that plaque erosion might be as
requent as 30% to 40% (17). More
requently seen in pre-menopausal
omen and smokers, erosion is charac-
erized by a neutral or negatively re-
odeled, thick-cap fibroatheroma (18).
n addition, compared with plaque rup-
ure, eroded plaques have less calcifica-
ion, abundant smooth muscle cells,
nd fewer macrophages (18). Although
rosion might occur, independent of
he degree of stenosis (19), detailed
nalysis in younger populations sug- bests a less stenotic lesion when com-
ared with plaque rupture (20). The
hrombogenic substrate in plaque ero-
ion is rather controversial. Contrary to
laque rupture, in which exposure to
he necrotic core is up to 6 times more
hrombogenic than all other compo-
ents (21), plaque erosion is character-
zed by no communication between the
ecrotic core and the lumen. As such,
xtracellular matrix like proteoglycans
22) or even tissue factor expressed by
ctivated smooth muscle cells might
lay a role (23). More interestingly, the
therosclerotic plaque by itself in ero-
ion might not be thrombogenic at all.
he plaque by itself might be an inno-
ent bystander. This fact was responsi-
Figure 2. Optical Coherence Tomography in Plaq
Total thrombotic occlusion of the left anterior desc
elevation myocardial infarction (A). Restoration of a
(B). Optical coherence tomography image after thr
after plaque rupture (1) and subocclusive thrombo
ﬂow and excellent angiographic expansion after co
and Tomasz Roleder, Mount Sinai Hospital, New Yole for the concept of vulnerable blood l24). As such, highly thrombogenic
lood might be at the center of plaque
rosion. In addition, plaque erosion is
haracterized by increased incidence of
oronary micro-thrombi, supporting
his hypothesis (25). Finally, approxi-
ately 2% to 7% of coronary thrombo-
is in STEMI might originate from
alcific nodules, more frequently seen
n the right coronary artery (26). These
esions require aggressive PCI in addi-
ion to thrombectomy and occasionally
thero-ablation to successfully prepare
he vessel and avoid incomplete expan-
ion of the stent.
Incidence of plaque erosion in clinical
practice. Different from autopsy data,
he real incidence of plaque erosion in
Rupture
ing artery during the acute phase of ST-segment
grade ﬂow after successful manual thrombectomy
ectomy (C) with documentation of residual cavity
2). Final angiogram with proper restoration of
ry stenting (D). Courtesy of Drs. Annapourna Kini
ew York.ue
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ronaiving patients is subject to controversy.
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294Small series using OCT for STEMI
suggest an incidence of 23% (27). Re-
cent studies on OCT and ACS have
focused on the type of thrombus and
the cavities observed in plaque rupture
(28). However, the data on alternative
pathological substrates, including plaque
erosion, calcified nodules, or intra-
plaque hemorrhage, was not reported
(29). As such, the real incidence of
plaque erosion seen in patients with
STEMI is difficult to estimate. How-
ever, studying the patients in which this
entity is commonly seen, we can get an
approximate idea. Pre-menopausal
women account for 4% of all patients
with STEMI (30). However, early after
menopause, the incidence might
change. Recently, the FAST-MI regis-
try (French Registry of Acute ST-
Elevation or non-ST-elevation Myo-
cardial Infarction) documented dramatic
increases in STEMI in the younger pop-
ulation from 1995 to 2010. The inci-
dence of STEMI in women below the
age of 60 has increased from 11.8% to
25.0% associated with significant in-
crease in smoking from 37% to 73%
(31). The role of plaque erosion in this
early post-menopausal female group re-
mains to be quantified but might be
higher than the one observed in older
populations. The incidence of plaque
erosion in young men might be esti-
mated as a sub-fraction of STEMI
observed in this age group. Men
younger than 45 years old account for
10% of STEMI patients (32). As such,
we can safely estimate that plaque ero-
sion might be responsible for STEMI
in 15% of cases.
Successful treatment for plaque erosion:
stents, thrombectomy, or both? Coro-
nary stents with proper adjunctive
pharmacotherapy provide excellent suc-
cess rates for all patients with STEMI,
independent of the pathophysiology.
Stents are associated with low in-
hospital mortality and re-occlusion
rates of 2% and 2%, respectively (6). In
addition, coronary stenting restores
laminar flow, reducing the thromboge-
nicity associated with the turbulentflow seen in high-shear stress stenotic
lesions. The contribution of thrombec-
tomy to coronary stenting in STEMI is
significant, improving epicardial flow
and reducing thrombus burden and dis-
tal embolization. However, a recent
meta-analysis of 21 randomized trials
showed no reduction in 30-day mortal-
ity or reinfarction with thrombectomy
in STEMI. A trend in higher risk of
stroke was observed with thrombec-
tomy (p  0.06). Manual but not
mechanical thrombectomy significantly
improved Thrombolysis In Myocardial
Infarction flow grade 3 and myocardial
reperfusion, mostly in patients with
documented thrombosis at baseline an-
giography (33).
Thrombectomy alone for erosion: risk of
re-occlusion. The risk of re-occlusion
fter successful thrombectomy alone is
nclear. However, re-occlusion rates
fter thrombolysis in STEMI are as
igh as 29% within the first year (34).
his translated into a cardiac mortality
f 27% at 10 years (34). Multiple fac-
ors are responsible for re-occlusion,
ncluding persistence of the thrombo-
enic substrate, geometric and rheo-
ogical factors related to the stenosis,
nd thrombin-bound to residual clot
35). All these factors are significantly
meliorated with effective scaffolding
evices like bare-metal and drug-
luting stents. This led to a 57% reduc-
ion in re-occlusion rates with PCI
hen compared with thrombolysis (8).
s such, coronary stents are the treat-
ent of choice for all types of STEMI.
oing away from stenting and recom-
ending thrombectomy alone might
e considered hypothesis-generating, at
est. Additional studies are mandatory
efore this therapy, although attractive
nd innovative, can be considered in
linical practice.
Routine use of intravascular imaging with
OCT during STEMI. The clinical benefits
of routine OCT during STEMI have
not been properly established. OCT
might provide valuable data before and
after the procedure, mostly related to
vessel size, plaque morphology, plaque tprotrusion, residual dissections, and ad-
equate stent-vessel wall apposition
(36). However, the main objective of
PCI during STEMI is the immediate
restoration of Thrombolysis In Myo-
cardial Infarction flow grade 3, with
resolution of symptoms and normaliza-
tion of ST-segment elevation. Further-
more, current penetration of OCT in
the United States is very low and re-
quires a learning curve not only for
performance but most importantly for
interpretation. Adding routine OCT to
every single STEMI to look for erosion
will increase procedural time, with the
risk of increasing complications in this
group of potentially unstable patients.
Is this the right time to change clinical
practice? We have witnessed an amaz-
ng progress in the treatment of
TEMI in the last 2 decades. This is a
lear example how change is funda-
ental for improvement but must be
upported with randomized controlled
rials. Manual thrombectomy com-
leted by coronary stenting offers excel-
ent results in STEMI, particularly in
atients presenting early. There will
ertainly be few cases (15% in clinical
ractice) in which plaque erosion is the
redominant morphology underneath
he occlusive thrombus. In these cases,
hrombectomy alone as the solo ther-
py for STEMI might have a role. The
rovocative series presented by Prati et
l. (37) in this issue of iJACC clearly tell
s that some patients can do very well
ith this therapy alone. However, to
roperly identify this minority of cases,
e will need to perform OCT in the
reat majority of patients. The risk/
enefit ratio associated with this ap-
roach is controversial, increasing pro-
edural time with potential adverse
onsequences. Nevertheless, saving a
atient from a permanent metallic
rosthesis is certainly worth the effort
nvolved in testing this hypothesis pro-
pectively, in a randomized controlled
rial. We must be open to change,
specially when we see opportunities
hat benefit the great majority, with
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295very low harm to the minority. Not
completely sure if the opposite might
also work . . . as well.
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